Provided by Tiger Trade Technology Pte. Ltd.

Biomarin Pharmaceutical

66.12
+1.051.61%
Post-market: 66.120.00000.00%19:30 EDT
Volume:1.36M
Turnover:89.66M
Market Cap:12.78B
PE:174.47
High:66.36
Open:65.03
Low:65.02
Close:65.07
52wk High:70.98
52wk Low:49.26
Shares:193.27M
Float Shares:192.12M
Volume Ratio:0.75
T/O Rate:0.71%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3790
EPS(LYR):1.80
ROE:1.18%
ROA:3.26%
PB:2.02
PE(LYR):36.73

Loading ...

BioMarin Pharmaceutical (BMRN) Receives a Buy from Guggenheim

TIPRANKS
·
Jun 03

Centene, Deckers and 14 Other 'Dividend Hopefuls' -- Barrons.com

Dow Jones
·
Jun 02

Capricor names Michael Maurer chief commercial officer

Reuters
·
May 29

BioMarin Pharmaceutical (BMRN) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
May 25

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
May 24

BioMarin Pharmaceutical Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
May 23

BioMarin price target lowered to $111 from $116 at Canaccord

TIPRANKS
·
May 22

BioMarin's drug shows significant growth gains in children in late-stage trial

Reuters
·
May 21

BioMarin Says Phase 3 Study of Voxzogo Shows Patient Improvements

Dow Jones
·
May 21

BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial

TIPRANKS
·
May 21

BioMarin plans FDA filing in Q3 2026 for Voxzogo in hypochondroplasia

Reuters
·
May 21

Biomarin Pharmaceutical Inc: Safety Findings Consistent With Established Profile in Achondroplasia

THOMSON REUTERS
·
May 21

Biomarin Pharmaceutical Inc - No New Safety Signals Identified in Phase 3 Study

THOMSON REUTERS
·
May 21

Biomarin Pharmaceutical Inc - Phase 3 Study Shows 2.33 Cm/Yr Increase in Annualized Growth Velocity at Week 52

THOMSON REUTERS
·
May 21

Biomarin Announces Positive Phase 3 Pivotal Study Results for Voxzogo® (Vosoritide) in Children With Hypochondroplasia

THOMSON REUTERS
·
May 21

Biomarin Pharmaceutical Inc - Plans FDA Supplemental Nda Submission for Voxzogo in Q3 2026

THOMSON REUTERS
·
May 21

U.S. RESEARCH ROUNDUP-CAVA Group, Eagle Materials, Vertiv

Reuters
·
May 20

Analysts Offer Insights on Healthcare Companies: InfuSystem Holdings (INFU) and BioMarin Pharmaceutical (BMRN)

TIPRANKS
·
May 20

BioMarin Pharmaceutical Is Maintained at Buy by B of A Securities

Dow Jones
·
May 20

BioMarin price target lowered to $80 from $85 at BofA

TIPRANKS
·
May 19